Table 3 The indirect-comparison results of efficacy and safety of MAbs targeting CD38, SLAMF7 and PD-1/PD-L1 groups
Outcomes | Antibodies targeting CD38 vs SLAMF7 | Antibodies targeting CD38 vs PD-1/PD-L1 | Antibodies targeting SLAMF7 vs PD-1/PD-L1 |
|---|---|---|---|
PFR - HR(95CI) | 0.662 (0.543,0.806) | 0.317 (0.221,0.454) | 0.479 (0.328,0.699) |
OS - HR(95CI) | 0.812 (0.584,1.127) | NA | NA |
ORR - RR(95CI) | 0.976 (0.763,1.248) | 1.247 (1.035,1.503) | 1.278 (0.968,1.688) |
CR or better-RR(95CI) | 2.253 (1.284,3.955) | NA | NA |
VGPR or better-RR(95CI) | 1.304 (0.956,1.778) | NA | NA |
VGPR - RR(95CI) | 0.993 (0.671,1.468) | NA | NA |
PR- RR(95CI) | 1.522 (0.876,2.642) | NA | NA |
SD - RR(95CI) | 0.636 (0.368,1.099) | NA | NA |
Neutropenia - RR(95CI) | 1.818 (1.41,2.344) | 1.207 (0.94,1.55) | 0.664 (0.515,0.855) |
Anemia-RR(95CI) | 0.932 (0.656,1.323) | 0.566 (0.332,0.963) | 0.607 (0.346,1.064) |
Thrombocytopenia -RR(95CI) | 1.186 (0.83,1.694) | NA | NA |
Lymphopenia -RR(95CI) | 1.043 (0.753,1.444) | NA | NA |
Pneumonia-RR(95CI) | 1.144 (0.72,1.817) | 1.325 (0.725,2.419) | 1.158 (0.58,2.311) |
Diarrhea-RR(95CI) | 1.00 (0.497,2.014) | 0.446 (0.102,1.956) | 0.446 (0.095,2.105) |
Fatigue-RR(95CI) | 1.681 (0.903,3.13) | 5.00 (1.717,14.56) | 2.975 (0.998,8.867) |